Advertisement
Research Article

Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

  • Caterina Guinovart,

    Affiliations: Barcelona Centre for International Health Research, Hospital Clínic/IDIBAPS, Universitat de Barcelona, Barcelona, Spain, Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique

    X
  • John J. Aponte,

    Affiliations: Barcelona Centre for International Health Research, Hospital Clínic/IDIBAPS, Universitat de Barcelona, Barcelona, Spain, Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique

    X
  • Jahit Sacarlal,

    Affiliations: Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique, Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique

    X
  • Pedro Aide,

    Affiliations: Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique, Instituto Nacional de Saúde, Maputo, Mozambique

    X
  • Amanda Leach,

    Affiliation: GlaxoSmithKline Biologicals, Rixensart, Belgium

    X
  • Quique Bassat,

    Affiliations: Barcelona Centre for International Health Research, Hospital Clínic/IDIBAPS, Universitat de Barcelona, Barcelona, Spain, Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique

    X
  • Eusébio Macete,

    Affiliations: Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique, Direcçao Nacional de Saúde, Ministério de Saúde, Maputo, Mozambique

    X
  • Carlota Dobaño,

    Affiliations: Barcelona Centre for International Health Research, Hospital Clínic/IDIBAPS, Universitat de Barcelona, Barcelona, Spain, Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique

    X
  • Marc Lievens,

    Affiliation: GlaxoSmithKline Biologicals, Rixensart, Belgium

    X
  • Christian Loucq,

    Affiliation: PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America

    X
  • W. Ripley Ballou,

    Affiliation: GlaxoSmithKline Biologicals, Rixensart, Belgium

    X
  • Joe Cohen,

    Affiliation: GlaxoSmithKline Biologicals, Rixensart, Belgium

    X
  • Pedro L. Alonso mail

    palonso@clinic.ub.es

    Affiliations: Barcelona Centre for International Health Research, Hospital Clínic/IDIBAPS, Universitat de Barcelona, Barcelona, Spain, Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique

    X
  • Published: April 14, 2009
  • DOI: 10.1371/journal.pone.0005165

About the Authors

Caterina Guinovart, John J. Aponte, Quique Bassat, Carlota Dobaño, Pedro L. Alonso
Barcelona Centre for International Health Research, Hospital Clínic/IDIBAPS, Universitat de Barcelona, Barcelona, Spain
Caterina Guinovart, John J. Aponte, Jahit Sacarlal, Pedro Aide, Quique Bassat, Eusébio Macete, Carlota Dobaño, Pedro L. Alonso
Centro de Investigação em Saúde da Manhiça, Manhiça, Maputo, Mozambique
Jahit Sacarlal
Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique
Pedro Aide
Instituto Nacional de Saúde, Maputo, Mozambique
Amanda Leach, Marc Lievens, W. Ripley Ballou, Joe Cohen
GlaxoSmithKline Biologicals, Rixensart, Belgium
Eusébio Macete
Direcçao Nacional de Saúde, Ministério de Saúde, Maputo, Mozambique
Christian Loucq
PATH Malaria Vaccine Initiative, Bethesda, Maryland, United States of America

Corresponding Author

Email: palonso@clinic.ub.es

Competing Interests

MVI supports the development and testing of a number of malaria vaccines, including some that can be regarded as competitors. AL, ML, WRB* and JC are currently employed by GSK Biologicals or *were employed at the time the study was conducted. AL, WRB and JC hold shares in GlaxoSmithKline. JC and WRB are inventors on patents relating to malaria vaccines. None of the other authors in this paper have declared a conflict of interest.

Author Contributions

Conceived and designed the experiments: CG JJA CD PLA. Performed the experiments: CG JJA JS PA QB EM PLA. Analyzed the data: JJA ML. Wrote the paper: CG CD CL PLA. Contributed to the interpretation of the results and write up of the manuscript: JJA JS AL CL RB JC. Participated in the design and implementation of the original trial: JS AL RB JC.